Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025
Rhea-AI Summary
Dermata Therapeutics (Nasdaq:DRMA) announced a strategic pivot to develop and commercialize direct-to-consumer skincare under the new brand Tome, planning to launch its first product, the Foundational Treatment, in mid-2026. The company reported year-end 2025 cash of $7.5 million and raised $15.4 million in gross proceeds during 2025 and early 2026, which it expects will fund operations into the first quarter of 2027. Dermata also noted a $5.3 million reduction in R&D spending versus 2024 following completion of the STAR-1 acne study and withdrew its IND for XYNGARI to focus on the DTC strategy.
Positive
- Cash balance of $7.5M as of December 31, 2025
- Raised $15.4M in gross proceeds during 2025 and early 2026
- Planned DTC launch: Foundational Treatment in mid-2026
- R&D expenses down $5.3M YoY after STAR-1 completion
Negative
- Operations used $7.8M cash in 2025
- Company expects runway only into Q1 2027
- Withdrew IND for XYNGARI to pivot away from prescription pathway
News Market Reaction – DRMAW
In the Mar 27 session, DRMAW declined 22.27%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 14 | Earnings and pivot | Positive | +9.4% | Announced DTC pivot and Q3 2025 financial results with acne kit plans. |
| Aug 13 | Earnings and trial data | Positive | +15.2% | Q2 2025 results with positive Phase 3 data and strengthened cash position. |
| May 14 | Earnings and trial update | Positive | -32.5% | Q1 2025 results and successful STAR-1 topline data with financing details. |
| Mar 17 | Year-end 2024 results | Positive | +15.5% | Year-end 2024 results with upcoming STAR-1 data and financing activity. |
| Nov 13 | Quarterly results | Positive | -7.6% | Q3 2024 results with STAR-1 enrollment progress and higher R&D spend. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings updates often triggered sizeable moves, with both strong rallies and sharp selloffs, indicating volatile reactions to similar corporate updates.
Recent earnings and corporate updates for Dermata have focused on its acne program, repeated positive Phase 3 STAR-1 data, and a gradual pivot toward over-the-counter and direct-to-consumer skincare. Cash balances previously ranged from $3.2M at year-end 2024 to $9.7M in Q1 2025, with financings extending runway into Q2 2026. Today’s year-end 2025 update continues that trajectory, highlighting a full strategic pivot to DTC skincare, materially lower R&D expenses, higher SG&A from marketing, and cash expected to fund operations into Q1 2027.
Key Terms
over-the-counter ("OTC") regulatory
investigational new drug application regulatory
phase 3 medical
clinical trial medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Dermata announced a strategic pivot to develop and commercialize direct-to-consumer ("DTC") skincare products under the brand name Tome -
- Dermata plans to launch its first DTC product, our Foundational Treatment, a once-weekly mask to support a skin renewal, in the middle of 2026 -
- Raised
SAN DIEGO, CA / ACCESS Newswire / March 26, 2026 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today highlighted recent corporate progress and reported financial results for the year ended December 31, 2025.
"We are extremely excited as we approach the planned launch of our first DTC product in the middle of 2026, as this will be an important milestone in our company's evolution," said Gerry Proehl, Chairman, President, and CEO of Dermata. "Our team has been extremely busy over the past few months since we announced in September 2025 our strategic pivot to sell direct-to-consumer skincare products. Since the announcement, we have recently revealed our new skincare brand, Tome, hired a new Vice President of Marketing to lead the brand, and are close to finalizing the commercial packaging for our first product," Mr. Proehl continued. "We believe we can leverage our deep knowledge from years of clinical dermatology to deliver DTC skincare products that are efficacious and accessible to consumers. With the cash raised from our recent financings, we believe we are in a good financial position for our planned product launches, with potential revenue to follow," concluded Mr. Proehl.
Kyra Peckaitis, Dermata's new Vice President of Marketing, commented, "Having recently joined Dermata, I've been incredibly energized by both the strength of the team and opportunity to create something truly differentiated in the skincare market. We are very excited to announce our first product by Tome, our Foundational Treatment, a once-weekly, foundational step designed to renew the appearance of the skin and improve tone and texture over time. Our Foundational Treatment will incorporate our hero ingredient, Spongillalacustris, a wildly harvested freshwater sponge that we call Bioneedle, to provide consumers with the feel of an aesthetician treatment at home." Ms. Peckaitis continued, "We decided to fast-track the launch of the Foundational Treatment as we see this product reaching a larger market, which can be used as the base product for any skincare routine. We continue to diligently work on our second product, our Clearing Treatment for acne, which we expect to launch for the sizable acne market shortly after launching our Foundational Treatment. In a crowded skincare landscape, we see a real opportunity to stand out by offering solutions that simplify routines while delivering meaningful improvements in how consumer's skin looks and feels, and we believe our Foundational Treatment and Clearing Treatment will do just that."
Corporate Highlights
Announced strategic pivot to DTC skincare company. In September 2025, Dermata announced that it was making a strategic shift from developing prescription dermatology products to developing and commercializing DTC skincare products. The Company is currently working on branding, packaging, and manufacturing to prepare for the expected launch of its first DTC product, a once-weekly, foundational routine to support skin renewal in the middle of 2026. The Company plans to sell multiple skincare products directly to consumers and directly to aestheticians and dermatologists for in-office treatments.
Announced the launch of its new skincare brand, Tome. In March 2026, Dermata revealed its new skincare brand, Tome, which aims to introduce "skintech" at home. The Tome skincare line will emphasize products Dermata believes can become the essential foundation of any well-rounded skincare routine. The Company plans to add multiple products to their Tome skincare portfolio that utilize time-tested remedies to simplify skincare routines.
Announced the hiring of Kyra Peckaitis as Vice President of Marketing. In March 2026, Ms. Peckaitis joined the Dermata team to lead the launch of its new Tome skincare brand. Prior to joining Dermata, Ms. Peckaitis worked at Coterie helping to build its DTC baby care brand. Ms. Peckaitis brings years of experience in DTC marketing and brand building.
Raised
$15.4 million in gross proceeds during 2025 and beginning of 2026. The funds raised during 2025, along with the proceeds from the Company's at-the-market facility in January 2026, are expected to fund its operations into the first quarter of 2027.
Announced positive topline data from its XYNGARI Phase 3 STAR-1 clinical trial in moderate-to-severe acne. In March 2025, Dermata announced that its STAR-1 study met all three primary endpoints by producing highly statistically significant results versus placebo at the end of study. In April 2025, Dermata also announced that XYNGARI achieved statistically significant separation from placebo after just 4 weeks, or only four treatments. The STAR-1 study tested Spongillalacustris as a treatment for moderate-to-severe acne, adding to the prior Phase 2b study where XYNGARI achieved statistically significant separation from placebo at all time points. However, the Company has since withdrawn the investigational new drug application for XYNGARI to pursue its new commercial strategy of selling DTC skincare products.
Anticipated Upcoming Milestones
Launch first DTC product, Foundational Treatment, in the middle of 2026. The Company is close to finalizing packaging for the upcoming launch of its Foundational Treatment. The Company believes the Foundational Treatment can be the base of any skincare routine, designed to renew the appearance of the skin and simplify skincare with a once-weekly application. The Company anticipates being ready to launch the Foundational Treatment in the middle of 2026.
Launch second DTC product, Clearing Treatment, an over-the-counter ("OTC") acne treatment. The Company is also working on finalizing its second DTC product, its Clearing Treatment, targeting consumers suffering from common forms of acne. This OTC acne treatment will incorporate an FDA approved OTC active ingredient along with the Company's Bioneedle, to provide patients with a targeted treatment for their acne. The Clearing Treatment is expected to launch shortly after the Foundational Treatment.
Year Ended 2025 Financial Results
As of December 31, 2025, the Company had
Research and development expenses were
Selling, general and administrative expenses increased by approximately
About Dermata Therapeutics
Dermata Therapeutics is a scientific leader in dermatologic solutions that recently announced a strategic pivot from pharmaceutical development to begin focusing on the development and commercialization of direct-to-consumer skincare solutions. The Company is currently developing a first-of-its-kind skin refresh and acne treatments that incorporates Dermata's Bioneedle. The Company plans to launch its initial product in the middle of 2026 with additional innovations planned to follow. Dermata is headquartered in San Diego, California. For more information, or to join our mailing list, please visit http://www.dermatarx.com/.
About Tome Skincare
Tome is Dermata's new skincare line focused on bringing about a new realm of skincare that is powerful, not punishing. Tome in its literal meaning is a large, important, scholarly book. Dermata intends to educate consumers with a brand that tells a skincare story rooted in science and history. Tome will consist of a line of skincare products utilizing Spongilla lacustris, a wildly harvested, freshwater sponge that has evolved over millions of years, for consumers that are compelled by history and science to find the most potent products for their skincare routine. Dermata believes its Tome skincare line will simplify existing skincare routines with essential ingredients that deliver results, without harmful extremes. Dermata expects to launch its first product in the middle of 2026 with additional product launches planned to follow. Start your skincare story at www.tomeskincare.com.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company's current beliefs and expectations and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but are not limited to, statements related to: Dermata's shift to prioritize DTC skincare products; the anticipated benefits of Dermata's strategic shift to prioritize DTC skincare products, including acceleration of its path to commercialization, reduction of regulatory burdens, and expansion into broader consumer markets; the success, cost, and timing of the launch of its planned or future DTC products, including Foundational Treatment; the expected timing and success of any planned or future DTC product launches, including Clearing Treatment; expectations for the success of the Company's products and their ability to generate revenue for the Company; the Company's expectations with regard to current cash and cash equivalents and the amount of time it will fund operations; and other factors described in the Company's filings with the Securities and Exchange Commission. These forward-looking statements are generally identified by the use of such words as "may," "could," "should," "would," "believe," "anticipate," "forecast," "estimate," "expect," "intend," "plan," "continue," "outlook," "will," "potential" and similar statements of a future or forward-looking nature. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in product development and commercialization. For a discussion of these and other factors, please refer to Dermata's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Dermata undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.
DERMATA THERAPEUTICS, INC.
Balance Sheets
December 31, 2025 | December 31, 2024 | |||||||
In thousands USD | ||||||||
Assets | ||||||||
Cash and cash equivalents | $ | 7,522 | $ | 3,162 | ||||
Prepaid expenses and other current assets | 342 | 372 | ||||||
Total assets | 7,864 | 3,534 | ||||||
Liabilities | ||||||||
Accounts payable | 461 | 808 | ||||||
Accrued liabilities | 1,180 | 1,165 | ||||||
Total liabilities | 1,641 | 1,973 | ||||||
Equity | 6,223 | 1,561 | ||||||
Total liabilities and equity | $ | 7,864 | $ | 3,534 | ||||
DERMATA THERAPEUTICS, INC.
Statements of Operations
Year Ended December 31, | ||||||||
2025 | 2024 | |||||||
In thousands, except share and per share data | ||||||||
Operating expenses | ||||||||
Research and development (1) | $ | 2,930 | $ | 8,204 | ||||
Selling, general and administrative (1) | 4,844 | 4,309 | ||||||
Total operating expenses | 7,774 | 12,513 | ||||||
Loss from operations | (7,774 | ) | (12,513 | ) | ||||
Interest income, net | 215 | 226 | ||||||
Net loss | $ | (7,559 | ) | $ | (12,287 | ) | ||
Net loss per common share, basic and diluted | $ | (8.16 | ) | $ | (80.32 | ) | ||
Weighted average common shares outstanding, basic and diluted | 926,192 | 152,974 | ||||||
(1) Includes the following stock-based compensation expense | ||||||||
Research and development | $ | 32 | $ | 251 | ||||
Selling, general and administrative | $ | 112 | $ | 406 | ||||
Investors:
Cliff Mastricola
Investor Relations
cmastricola@dermatarx.com
SOURCE: Dermata Therapeutics
View the original press release on ACCESS Newswire